ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy - - ARV-102 was well tolerated across all dose levels following 28 ...

Northwestern Medicine scientists have discovered that an FDA-approved compound promotes neuroprotective effects in experimental models of Parkinson's disease. The compound, N-acetyl-L-leucine (NALL), ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today ...

Partnership supports expanded biomarker discovery efforts within MJFF's Parkinson's Progression Markers Initiative MORRISVILLE, N.C., March 17, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader ...

Opinion editor’s note: Strib Voices publishes a mix of commentary online and in print each day. To contribute, click here. ••• Minnesota families struggling with Parkinson’s disease deserve better ...

The "world smells different" for people with Parkinson's disease, a discovery that could help doctors spot the condition sooner ...

BOWLING GREEN, Ky. — According to the Cleveland Clinic, there are over seven million people with Parkinson’s disease worldwide and of those, between 75 and 90% will develop speech or voice problems.

What should patients with Parkinson's disease know about anxiety, the factors that may increase anxiety, and treatment options?

Early prediction and identification of neurodegenerative diseases offers the best chance for prevention and treatment.